MedTrace Logo

Bioimaging Study of 89Zr-M7824 in NSCLC

NCT04297748 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-01-17

No results posted yet for this study

Summary

This is a bioimaging study of 89Zr-M7824 PET scans in patients with advanced or metastatic non-small cell lung cancer who will be receiving M7824 alone or with standard of care chemotherapy. M7824 is a bifunctional fusion protein that combines an anti-PD-L1 antibody and the extracellular domain of TGFβ receptor II (TGFβRII) as a TGFβ neutralizing 'trap', into a single molecule.

Conditions

Interventions

COMBINATION_PRODUCT

89Zirconium-M7824

PET imaging agent

DRUG

M7824

Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.

Sponsors & Collaborators

  • Merck Healthcare KGaA

    collaborator UNKNOWN

  • Austin Health

    collaborator OTHER_GOV

  • Olivia Newton-John Cancer Research Institute

    lead OTHER

Principal Investigators

  • Hui K Gan, MBBS · Austin Health

  • Andrew M Scott, MBBS · Austin Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04297748 on ClinicalTrials.gov